ME00521B - Derivati imidazola sa afinitetom prema aktivnosti alfa 2 receptora - Google Patents

Derivati imidazola sa afinitetom prema aktivnosti alfa 2 receptora

Info

Publication number
ME00521B
ME00521B MEP-2008-864A MEP86408A ME00521B ME 00521 B ME00521 B ME 00521B ME P86408 A MEP86408 A ME P86408A ME 00521 B ME00521 B ME 00521B
Authority
ME
Montenegro
Prior art keywords
substituted
unsubstituted
affinity
alpha
prodrug forms
Prior art date
Application number
MEP-2008-864A
Other languages
English (en)
Inventor
Tomi Järvinen
Riku Niemi
Juhani Huuskonen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of ME00521B publication Critical patent/ME00521B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Ovaj pronalazak se odnosi na nove proljekove izvedene iz MPV -2426, na postupke za dobijanje navedenih oblika prolijeka, na farmaceutske kompozicije koji sadrže takve oblike prolijeka i na postupke upotrebe tih oblika prolijeka. Jedinjenje opšte formule (I) ili njegove farmaceutski prihvatljive soli ili hidrati, gdje R predstavlja nesupstituisan ili supstituisan niži alkil, nesupstituisan ili supstituisan aril, nesupstituisan ili supstituisan cikloalkil, nesupstituisan ili supstituisan heteroaril, nesupstituisanu ili supstituisanu nižu alkilamino ili zasićenu heterocikličnu grupu sa pet ili šest članova koja sadrži jedan ili dva atoma azota.
MEP-2008-864A 2002-12-05 2003-12-05 Derivati imidazola sa afinitetom prema aktivnosti alfa 2 receptora ME00521B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20022159A FI20022159A0 (fi) 2002-12-05 2002-12-05 Uusia farmaseuttisia yhdisteitä
PCT/FI2003/000933 WO2004050635A2 (en) 2002-12-05 2003-12-05 Imidazol derivatives having affinity for alpha 2 receptors activity

Publications (1)

Publication Number Publication Date
ME00521B true ME00521B (me) 2011-10-10

Family

ID=8565048

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-864A ME00521B (me) 2002-12-05 2003-12-05 Derivati imidazola sa afinitetom prema aktivnosti alfa 2 receptora

Country Status (27)

Country Link
US (1) US7759496B2 (me)
EP (1) EP1572198B1 (me)
JP (1) JP4667042B2 (me)
KR (1) KR20050114603A (me)
CN (1) CN100560070C (me)
AT (1) ATE323484T1 (me)
BR (1) BR0317024A (me)
CA (1) CA2508335C (me)
CY (1) CY1105699T1 (me)
DE (1) DE60304741T2 (me)
DK (1) DK1572198T3 (me)
EA (1) EA008251B1 (me)
ES (1) ES2262031T3 (me)
FI (1) FI20022159A0 (me)
HR (1) HRP20050617B1 (me)
IL (1) IL168882A (me)
IS (1) IS2282B (me)
ME (1) ME00521B (me)
MX (1) MXPA05005963A (me)
NO (1) NO330392B1 (me)
NZ (1) NZ540466A (me)
PL (1) PL216530B1 (me)
PT (1) PT1572198E (me)
RS (1) RS52571B (me)
SI (1) SI1572198T1 (me)
WO (1) WO2004050635A2 (me)
ZA (1) ZA200504533B (me)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003624B2 (en) 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
US7700592B2 (en) 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
CN101374830A (zh) 2005-08-25 2009-02-25 先灵公司 α2C肾上腺素受体激动剂
US8324213B2 (en) 2008-10-07 2012-12-04 Merck Sharp & Dohme Corp. Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) * 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
JPH10195056A (ja) * 1996-11-12 1998-07-28 Takeda Chem Ind Ltd 縮合ベンゼン誘導体、その製造法および剤
JP4647785B2 (ja) * 1998-09-28 2011-03-09 オリオン コーポレーション 脊椎内、髄腔内または硬膜外投与用医薬の製造における３−（１ｈ−イミダゾール−４−イルメチル）−インダン−５−オールの用途
CA2388979C (en) * 1999-10-29 2010-09-14 Orion Corporation Treatment or prevention of hypotension and shock with use of an imidazole derivative
US6388090B2 (en) * 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
FI20000073A0 (fi) * 2000-01-14 2000-01-14 Orion Yhtymae Oy Uusia imidatsolijohdannaisia
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7439268B2 (en) * 2003-07-18 2008-10-21 Idexx Laboratories Compositions containing prodrugs of florfenicol and methods of use

Also Published As

Publication number Publication date
HRP20050617A2 (en) 2005-10-31
ATE323484T1 (de) 2006-05-15
IL168882A (en) 2010-05-31
IS2282B (is) 2007-09-15
EA200500922A1 (ru) 2005-12-29
IS7911A (is) 2005-06-23
DE60304741T2 (de) 2007-04-12
JP4667042B2 (ja) 2011-04-06
MXPA05005963A (es) 2005-08-18
EP1572198A2 (en) 2005-09-14
ES2262031T3 (es) 2006-11-16
NO20053302D0 (no) 2005-07-05
RS52571B (en) 2013-04-30
CA2508335A1 (en) 2004-06-17
DE60304741D1 (de) 2006-05-24
PL216530B1 (pl) 2014-04-30
CN100560070C (zh) 2009-11-18
CN1735409A (zh) 2006-02-15
FI20022159A0 (fi) 2002-12-05
RS20050428A (en) 2007-08-03
NO20053302L (no) 2005-07-05
EP1572198B1 (en) 2006-04-19
CY1105699T1 (el) 2010-12-22
WO2004050635A3 (en) 2004-09-02
ZA200504533B (en) 2006-03-29
BR0317024A (pt) 2005-10-25
NO330392B1 (no) 2011-04-04
DK1572198T3 (da) 2006-07-03
NZ540466A (en) 2008-04-30
WO2004050635A2 (en) 2004-06-17
SI1572198T1 (sl) 2006-08-31
HRP20050617B1 (hr) 2013-07-31
PL377530A1 (pl) 2006-02-06
US7759496B2 (en) 2010-07-20
EA008251B1 (ru) 2007-04-27
AU2003302622A1 (en) 2004-06-23
PT1572198E (pt) 2006-08-31
US20060178417A1 (en) 2006-08-10
JP2006509780A (ja) 2006-03-23
CA2508335C (en) 2011-09-13
KR20050114603A (ko) 2005-12-06

Similar Documents

Publication Publication Date Title
ATE556058T1 (de) 1-(2h)-isochinolonderivat
MEP8409A (en) Fused heterocyclic compound
ME00590A (en) N-(aminoheteroaryl)-1h-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof
EA200601235A1 (ru) Производные тиазола
RS52099B (en) SUBSTITUTED BENZIMIDAZOLES AS KINASE INHIBITORS
ME00610B (me) 1 –heterociklilsulfonil, 2 –aminometil, 5– (hetero–) aril supstituisan 1–h–pirol derivati kao inhibitori lučenja kiseline
RS52978B (en) FUSIONED AMINO PIRIDIN AS HSP90 INHIBITORS
BR0009558A (pt) Composto derivado bicìclico heteroaromático, composição farmacêutica, e, uso de compostos derivados bicìclicos heteroaromáticos
BR0315405A (pt) Compostos inibidores da integrase tricìclica pré-organizados
DK1261602T3 (da) Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer
SE0400284D0 (sv) Novel compounds
YU67601A (sh) 1-arensulfonil-2-aril-pirolidin i derivati piperidina
PT1427727E (pt) Compostos que inibem a libertacao de citocinas inflamatorias
ATE276257T1 (de) Pyrazinonderivate
HRP20050617B1 (hr) Derivati imidazola s afinitetom prema aktivnosti alfa 2 receptora
DE60330758D1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
ATE377598T1 (de) Durch bicyclische aminogruppen substituierte verbindungen
RS51320B (sr) Derivati imidazohinolina kao veznici a3 receptora adenozina
RS51518B (en) NEW BENZOTIADIAZINE DERIVATIVES, PROCESSES OF THEIR PRODUCTION AND THE PHARMACEUTICAL MIXTURES CONTAINING THEME
RS54061B1 (en) QUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONCERNING THEM, AND THEIR APPLICATIONS
NO20023298D0 (no) Nye imidazolderivater
BR0308935A (pt) Inibidor de fosfodiesterase iv contendo derivado de piridilacrilamida
BRPI0610580B8 (pt) composto derivado de piperidina
ATE449760T1 (de) Nichtpeptidinhibitoren von matrixmetalloproteinasen
HRPK20070123B3 (en) Phenyl-piperazine derivatives as serotonin reuptake inhibitors